Patents Examined by Stanley Friedman
  • Patent number: 5071658
    Abstract: A method of treating the prostate by intraprostatic injection of zinc ions in a concentration effective to increase the amount of prostatic antibacterial factor and to inhibit the rate of prostatic growth. The treatment is applied to patients with prostatitis, to patients with benign adenomatous hyperplasia of the prostate after prostatic resection and to patients with early prostatic carcinoma as an alternative to surgery as needed to provide long-term remission. The treatment is also applied prophylactically to prevent the development of prostatitis, particularly in males of advanced age.
    Type: Grant
    Filed: July 23, 1990
    Date of Patent: December 10, 1991
    Inventor: Mostafa S. Fahim
  • Patent number: 5066648
    Abstract: The invention relates to pyroglutamic acid esters used as dermal penetration enhancers for therapeutic agents having poor skin permeation.
    Type: Grant
    Filed: September 13, 1990
    Date of Patent: November 19, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Jose Alexander, Takeru Higuchi, deceased
  • Patent number: 5064857
    Abstract: The invention relates to a liquid, bismuth containing medicinal product for the oral treatment of gastro-intestinal illnesses such as gastritis, ulcers, etc., caused by campylobacter.The invention provides a closed system, e.g. a single dose container or a multiple dose container with dosing device containing one or more portions of the bismuth containing medicinal product. In addition, a simple, inexpensive production process is proposed, in which the bismuth citrate is suspended in water, slightly heated and, accompanied by the addition of caustic potash solution/aqueous ammonia solution, is dissolved and set to a pH-value between 6.0 and 7.0 Subsequently an aqueous tripotassium citrate-citric acid solution is added and if necessary sterilized. The solution obtained is placed in a multidose container with dosing device, or is initially diluted with water to form a ready to drink solution, portioned into single dose containers and optionally sterilized.
    Type: Grant
    Filed: October 4, 1989
    Date of Patent: November 12, 1991
    Assignee: R. Pfleger Chemische Fabrik GmbH
    Inventors: Heinz Bertholdt, Dieter Michalczyk, Guenter Urban
  • Patent number: 5053429
    Abstract: This invention concerns novel methods employing compositions containing as an active antioxidant or antiinflammatory agent the amino acid methionine, and/or one or more related compounds including certain metabolic precursor compounds, for treating or inhibiting inflammation and inflammatory pain in a subject. The compounds include the methionine hydroxy analogs, as well as compounds having the structural formula I: ##STR1## and pharmaceutically acceptable N-(mono- and di-carboxylic acid) acyl derivatives and alkyl esters thereof, where n is an integer from 1 to 3.
    Type: Grant
    Filed: February 21, 1990
    Date of Patent: October 1, 1991
    Assignee: The Lithox Corporation, Inc.
    Inventors: Gerald P. Hirsch, Robert K. Bayless
  • Patent number: 4990534
    Abstract: Aralkyl esters are used to provide a potentiating effect on cholinergic responses.
    Type: Grant
    Filed: January 24, 1989
    Date of Patent: February 5, 1991
    Assignee: Aktiebolaget Astra
    Inventors: Gerd M. Hallnemo, Thomas Hogberg, Ulf H. Lindberg, Bengt C. J. Ulff, Sven Ove gren
  • Patent number: 4985443
    Abstract: To cure vitiligo without side effects, a disease characterized by cutaneous depigmentation, a treatment consisting in the oral administration of folic acid in daily doses from 1 to 50 mg. The treatment of vitiligo with folic acid can be enhanced by also using oral vitamin C and intramuscular vitamin B.sub.12.
    Type: Grant
    Filed: August 4, 1989
    Date of Patent: January 15, 1991
    Inventor: Leopoldo F. Montes
  • Patent number: 4886783
    Abstract: This invention relates to a method for administering systemically active agents including therapeutic agents through the skin or mucosal membranes of humans and animals in a transdermal device or formulation comprising topically administering with said systemic agent an effective amount of a membrane penetration enhancer having the structural formula ##STR1## wherein each X, Y and Z may represent oxygen, sulfur or two hydrogen atoms, provided however that, when Z represents two hydrogen atoms, both X and Y represent oxygen or sulfur and when Z represents oxygen or sulfur at least one of X and Y must represent oxygen or sulfur; m is 2-6; R' is H or a lower alkyl group having 1-4 carbon atoms; n is 0-16 and R is --CH.sub.3, ##STR2## wherein R" is H or halogen.
    Type: Grant
    Filed: August 17, 1988
    Date of Patent: December 12, 1989
    Assignee: Nelson Research & Development Co.
    Inventors: Gevork Minaskanian, James V. Peck